Your browser doesn't support javascript.
loading
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman, Jeff P; Egyed, Miklos; Jurczak, Wojciech; Skarbnik, Alan; Pagel, John M; Flinn, Ian W; Kamdar, Manali; Munir, Talha; Walewska, Renata; Corbett, Gillian; Fogliatto, Laura Maria; Herishanu, Yair; Banerji, Versha; Coutre, Steven; Follows, George; Walker, Patricia; Karlsson, Karin; Ghia, Paolo; Janssens, Ann; Cymbalista, Florence; Woyach, Jennifer A; Ferrant, Emmanuelle; Wierda, William G; Munugalavadla, Veerendra; Yu, Ting; Wang, Min Hui; Byrd, John C.
Afiliação
  • Sharman JP; Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA. Jeff.Sharman@USONCOLOGY.COM.
  • Egyed M; Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary.
  • Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
  • Skarbnik A; Novant Health Cancer Institute, Charlotte, NC, USA.
  • Pagel JM; Swedish Cancer Institute, Center for Blood Disorders and Stem Cell Transplantation, Seattle, WA, USA.
  • Flinn IW; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA.
  • Kamdar M; University of Colorado Cancer Center, Aurora, CO, USA.
  • Munir T; Haematology, Haematological Malignancy Diagnostic Service (HMDS), St. James's Institute of Oncology, Leeds, UK.
  • Walewska R; Cancer Care, University Hospitals Dorset, Bournemouth, UK.
  • Corbett G; Tauranga Hospital, Tauranga, New Zealand.
  • Fogliatto LM; Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil.
  • Herishanu Y; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Banerji V; Departments of Internal Medicine, Biochemistry & Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba Research Institute, Winnipeg, MB, Canada.
  • Coutre S; Stanford University School of Medicine, Stanford, CA, USA.
  • Follows G; Department of Haematology, Addenbrooke's Hospital NHS Trust, Cambridge, UK.
  • Walker P; Peninsula Health and Peninsula Private Hospital, Frankston, Melbourne, VIC, Australia.
  • Karlsson K; Skåne University Hospital, Lund, Sweden.
  • Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy.
  • Janssens A; University Hospitals Leuven, Leuven, Belgium.
  • Cymbalista F; Bobigny: Hématologie, CHU Avicennes, Bobigny, France.
  • Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
  • Ferrant E; Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie Clinique, Pierre-Bénite, France.
  • Wierda WG; Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, USA.
  • Munugalavadla V; AstraZeneca, South San Francisco, CA, USA.
  • Yu T; AstraZeneca, South San Francisco, CA, USA.
  • Wang MH; AstraZeneca, South San Francisco, CA, USA.
  • Byrd JC; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Leukemia ; 36(4): 1171-1175, 2022 04.
Article em En | MEDLINE | ID: mdl-34974526

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Linfocítica Crônica de Células B Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Leukemia Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos